| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Neurosciences Research Institute (Drs. Harding and Wild, and K.A. Robertson), School of Life and Health Sciences, Aston University, Birmingham, UK; Clinical Pharmacology (Dr. Rietbrock), Institute of Pharmacology, University of Cologne, Germany; and Global Pharmacoepidemiology (Dr. Martinez), Aventis Pharmaceuticals, Bridgewater, NJ.
Address correspondence and reprint requests to Professor G.F.A. Harding, Clinical Neurophysiology Unit, Neurosciences Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK; e-mail: g.f.a.harding{at}aston.ac.uk
OBJECTIVE: To separate the retinal electrophysiologic markers associated with vigabatrin-attributed visual field loss (VGB-VFL) from those associated with current vigabatrin therapy.
METHODS: A nonrandomly selected cohort of 8 previous and 18 current vigabatrin users and a reference cohort of 8 never vigabatrin-treated patients with epilepsy receiving other antiepilepsy drugs (AED) underwent electro-oculography (EOG), electroretinography (ERG), and automated static threshold perimetry. A cohort of 22 normal subjects underwent ERG. The validity of the retinal electrophysiologic variables to detect the presence and severity of VGB-VFL was assessed using receiver operator characteristic curves.
RESULTS: Of 26 patients exposed to vigabatrin, 18 exhibited VGB-VFL. No patients receiving alternative AED showed this type of visual field abnormality. The presence and severity of VGB-VFL was significantly associated with the latency (implicit time) and amplitude of the ERG cone function. The amplitude of the cone flicker response was the strongest predictor of VGB-VFL and revealed a sensitivity of 100% at a specificity of 75%. The EOG, the photopic and scotopic ERG, and the latency of the ERG second oscillatory potential (OP2) were not significantly related to the presence of VGB-VFL. Vigabatrin therapy was significantly associated with the photopic amplitude, the scotopic a-wave latency, and the latency of OP2.
CONCLUSION: In patients who cannot perform reliable perimetry, the cone-specific ERG flicker amplitude provides the best screening method for detecting VGB-VFL.
This article has been cited by other articles:
|
|
 |
|
  M. B. Jameson, D. M. Sharp, J. I. Sissingh, C. R. Hogg, P. I. Thompson, M. J. McKeage, M. Jeffery, S. Waller, G. Acton, C. Green, et al. Transient Retinal Effects of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, ASA404), an Antitumor Vascular-Disrupting Agent in Phase I Clinical Trials Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2553 - 2559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wild, C. R. Robson, A. L. Jones, I. A. Cunliffe, and P. E. M. Smith Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hammoudi, S. S. F. Lee, A. Madison, G. Mirabella, J. R. Buncic, W. J. Logan, O. C. Snead, and C. A. Westall Reduced Visual Function Associated with Infantile Spasms in Children on Vigabatrin Therapy Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Thiele Managing Epilepsy in Tuberous Sclerosis Complex J Child Neurol, September 1, 2004; 19(9): 680 - 686. [Abstract] [PDF]
|
|
|
|
 |
|
 J. McDonagh, L.J. Stephen, F.M. Dolan, S. Parks, G.N. Dutton, K. Kelly, D. Keating, G.J. Sills, and M.J. Brodie Peripheral retinal dysfunction in patients taking vigabatrin Neurology, December 23, 2003; 61(12): 1690 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Banin, R. S. Shalev, A. Obolensky, R. Neis, I. Chowers, and V. Gross-Tsur Retinal Function Abnormalities in Patients Treated With Vigabatrin Arch Ophthalmol, June 1, 2003; 121(6): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F.A. Harding, E. L. Spencer, J. M. Wild, M. Conway, and R. L. Bohn Field-specific visual-evoked potentials: Identifying field defects in vigabatrin-treated children Neurology, April 23, 2002; 58(8): 1261 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Koul, A Chacko, A Ganesh, S Bulusu, and K Al Riyami Vigabatrin associated retinal dysfunction in children with epilepsy Arch. Dis. Child., December 1, 2001; 85(6): 469 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Miller Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants Neurology, August 8, 2000; 55(3): 333 - 334. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
